lintuzumab: Clinical Trials

11 trials of lintuzumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 unknown, 1 terminated, 1 withdrawn. 7 Phase 2, 3 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 27Completed 4, Terminated 1, Unknown 1, Withdrawn 1
Phase 13Completed 3
Phase 31Unknown 1

Follow lintuzumab: new trials by email Literature Review of lintuzumab trials Research Report on lintuzumab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes
lintuzumab, 5-azacytidine - Leukemia, Myelodysplastic Syndromes
Phase 2TerminatedAlison Walker72009-11-012017-05-10
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
lintuzumab, lenalidomide - Myelodysplastic Syndrome (MDS)
Phase 1CompletedSeagen Inc.132008-03-012011-10-12
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
Lintuzumab (SGN-33), Low dose cytarabine, Placebo - Acute Myeloid Leukemia
Phase 2CompletedSeagen Inc.2112007-09-012015-01-07
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
lintuzumab - Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase 1CompletedSeagen Inc.822005-11-012014-12-18
Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia
lintuzumab - Leukemia
Phase 2UnknownJonsson Comprehensive Cancer Center2001-02-012013-12-19
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
filgrastim, lintuzumab, arsenic trioxide - Leukemia
Phase 2CompletedMemorial Sloan Kettering Cancer Center352000-11-012013-01-16
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia
lintuzumab, cytarabine, etoposide - Leukemia
Phase 3UnknownFacet Biotech2000-03-012013-11-06
Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome
lintuzumab - Myelodysplastic Syndromes
Phase 2WithdrawnEuropean Organisation for Research and Treatment of Cancer - EORTC1999-02-012012-07-11
Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
lintuzumab - Leukemia, Myelodysplastic Syndromes
Phase 1CompletedMemorial Sloan Kettering Cancer Center241996-10-012013-06-25
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
filgrastim, lintuzumab, cytarabine - Leukemia, Myelodysplastic Syndromes
Phase 2CompletedMemorial Sloan Kettering Cancer Center601996-07-012013-07-03
Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission
lintuzumab, cytarabine, idarubicin - Leukemia
Phase 2CompletedMemorial Sloan Kettering Cancer Center401994-08-012013-06-24

Conditions studied

Leukemia (9)  ·  Myelodysplastic Syndromes (6)  ·  Leukemia, Myeloid, Acute (5)  ·  Anemia, Refractory, with Excess of Blasts (4)  ·  Leukemia, Myelomonocytic, Chronic (4)  ·  Hematologic Diseases (3)  ·  Blast Crisis (2)  ·  Leukemia, Erythroblastic, Acute (2)  ·  Leukemia, Megakaryoblastic, Acute (2)  ·  Leukemia, Monocytic, Acute (2)  ·  Leukemia, Myeloid, Accelerated Phase (2)  ·  Leukemia, Myelomonocytic, Acute (2)  ·  Leukemia, Promyelocytic, Acute (2)  ·  Anemia, Refractory (1)  ·  Myeloproliferative Disorders (1)

Sponsors

Memorial Sloan Kettering Cancer Center (4)  ·  Seagen Inc. (3)  ·  Alison Walker (1)  ·  European Organisation for Research and Treatment of Cancer - EORTC (1)  ·  Facet Biotech (1)  ·  Jonsson Comprehensive Cancer Center (1)

Countries

United States (10)  ·  Belgium (2)  ·  France (2)  ·  Germany (2)  ·  Netherlands (2)  ·  United Kingdom (2)  ·  Austria (1)  ·  Canada (1)  ·  Denmark (1)  ·  Norway (1)  ·  Switzerland (1)

Top investigators

Eric Sievers, MD (2)  ·  Joseph G. Jurcic, MD (2)  ·  Alison Walker, MD (1)  ·  Christos E. Emmanouilides, MD (1)  ·  Daniel Levitt, MD, PhD (1)  ·  David A. Scheinberg, MD, PhD (1)  ·  Eric Sievers, M.D. (1)  ·  Heinz Zwierzina, MD (1)  ·  Peter Maslak, MD (1)

Results publications

PMID 19557623, PMID 22801961

NIH funding

P30CA016042 (1)